Hepatitis C

April 30th 2024

Findings highlight an increase in hospitalization among pregnant patients with HCV, further describing age’s impact on mortality, cirrhosis, preterm births, and stillbirths.

April 25th 2024

Tenofovir disoproxil fumarate was safe and effective for preventing mother-to-child transmission of HBV, but discontinuation was linked to postpartum hepatitis flares.

April 18th 2024

The modified difference-in-differences analysis found notable increases in DAA use after state Medicaid programs relaxed certain coverage restrictions.

April 12th 2024

Although overall engagement in the HCV care cascade improved after the introduction of DAAs, vulnerable subgroups still received less testing and treatment.